Evidence map›Paper›PMID 30150443›Full record

ArticleIn vivo (Athens, Greece)

Peak of Standardized Uptake Value in Oral Cancer Predicts Survival Adjusting for Pathological Stage.

Hidenori Suzuki, Tsuneo Tamaki, Masami Nishio, Shintaro Beppu, Nobuaki Mukoyama, Nobuhiro Hanai, Daisuke Nishikawa, Yusuke Koide, Yasuhisa Hasegawa

Abstract read
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Glycolytic pathway candidate markers in the prognosis of oral squamous cell carcinoma: a systematic review with meta-analysis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Molecular imaging
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hidenori SuzukiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan hi.suzuki@aichi-cc.jp.
Tsuneo TamakiDepartment of East Nagoya Imaging Diagnosis Center, Nagoya, Japan.
Masami NishioDepartment of Radiology, Nagoya Positron Emission Tomography Imaging Center, Nagoya, Japan.
Shintaro BeppuDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Nobuaki MukoyamaDeparment of Othorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nobuhiro HanaiDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Daisuke NishikawaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Yusuke KoideDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Yasuhisa HasegawaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTo predict survival outcomes of different patients with the same stage of disease is difficult. The possible correlation between PATIENTS AND

methods

resultsA peak of standardized uptake value of primary tumor (p-SUVpeak) of ≥14.1 was significantly correlated with shorter overall survival by univariate and multivariate analyses adjusted for the pathological TNM stage. A p-SUVpeak of ≥14.1 was significantly associated with shorter local recurrence-free survival and disease-free survival.

conclusionA higher p-SUVpeak on pretreatment

Indexed as

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAdultAgedCarcinoma, Squamous CellFemaleHumansMaleMiddle AgedMouth NeoplasmsNeoplasm MetastasisNeoplasm StagingPrognosisRadiopharmaceuticalsSurvival AnalysisFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG-PET/CTOral squamous cell carcinomaoverall survivalSUVpeakUICC8th

Identifiers

PMID30150443
PMCPMC6199585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.